Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 6/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KLK7 | P49862 | 1/20 | 0.33 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27546125 | 1.00 | SLC7A5 (0.44) | SLC7A5ADRB2ADRB1ADRB3PPARA | |
| SCHEMBL4982689 | 0.87 | SLC7A5 (0.50) | SLC7A5PPARAPPARGCTSSKDM4E | |
| SCHEMBL27521591 | 0.87 | SLC7A5 (0.50) | SLC7A5PPARAPPARGCTSSKDM4E | |
| SCHEMBL27537266 | 0.86 | CTSB (0.44) | SLC7A5PPARAPPARGCTSS | |
| SCHEMBL4978211 | 0.86 | CTSB (0.44) | SLC7A5PPARAPPARGCTSS | |
| SCHEMBL4981310 | 0.83 | PPARA (0.49) | SLC7A5ADRB2ADRB1ADRB3PPARA | |
| SCHEMBL4979372 | 0.82 | PPARA (0.60) | SLC7A5ADRB2ADRB1ADRB3PPARA | |
| SCHEMBL27519734 | 0.82 | PPARA (0.60) | SLC7A5ADRB2ADRB1ADRB3PPARA | |
| SCHEMBL8173917 | 0.81 | SLC7A5 (0.43) | SLC7A5ADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL6218326 | 0.81 | CTSB (0.47) | ADRB2ADRB1ADRB3PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027060-A1 | DIPEPTIDE NITRILES | ALTMANN EVA | 2008-01-31 | — | — | US | disclosed |
| US-20060235220-A1 | Dipeptide nitriles | MISSBACH MARTIN | 2006-10-19 | — | — | US | disclosed |
| EP-1283825-B1 | N-SUBSTITUTED PEPTIDYL NITRILES AS CYSTEINE CATHEPSIN INHIBITORS | NOVARTIS AG (CH) | 2005-09-14 | — | — | EP | disclosed |
| US-6812237-B2 | (ARYLAMINOACEAMIDO)ACETONITRILE DERIVATIVES | NOVARTIS AG (CH) | 2004-11-02 | — | — | US | disclosed |
| US-20040110806-A1 | Dipeptide derivatives | ALTMANN EVA (CH) | 2004-06-10 | — | — | US | disclosed |
| US-20040029814-A1 | Dipeptide nitriles | ALTMANN EVA (CH) | 2004-02-12 | — | — | US | disclosed |
| US-20030158256-A1 | N-substituted peptidyl nitriles as cysteine cathepsin inhibitors | NOVARTIS AG (CH) | 2003-08-21 | — | — | US | disclosed |
| EP-1283825-A1 | N-SUBSTITUTED PEPTIDYL NITRILES AS CYSTEINE CATHEPSIN INHIBITORS | Novartis AG (CH) | 2003-02-19 | — | — | EP | disclosed |
| US-6353017-B1 | INHIBITORS OF CATHESPINS USING DIPEPTIDE NITRILES AS ANTIINFLAMMATORY AGENTS AND ANTIARTHRITIC AGENTS | NOVARTIS AG (CH) | 2002-03-05 | — | — | US | disclosed |
| WO-2001087828-A1 | N-SUBSTITUTED PEPTIDYL NITRILES AS CYSTEINE CATHEPSIN INHIBITORS | NOVARTIS AG (CH) | 2001-11-22 | — | — | WO | disclosed |
| EP-1028942-A2 | DIPEPTIDE NITRILES | Novartis AG (CH) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999024460-A2 | DIPEPTIDE NITRILES | NOVARTIS AG (CH) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110806-A1 | Dipeptide derivatives | CTSL, CTSZ, CTSS | SLC7A5 123/4885ADRB2 4116/4885ADRB1 2890/4885 |
| US-20030158256-A1 | N-substituted peptidyl nitriles as cysteine cathepsin inhibitors | CTSS, CTSV, CTSF | SLC7A5 129/4885ADRB2 2050/4885ADRB1 2462/4885 |
| US-20040029814-A1 | Dipeptide nitriles | NOS1, CTSL, CTSS | SLC7A5 127/4885ADRB2 3285/4885ADRB1 1963/4885 |
| US-20060235220-A1 | Dipeptide nitriles | CTSL, CTSS, CTSB | SLC7A5 184/4885ADRB2 3888/4885ADRB1 2493/4885 |
| US-20080027060-A1 | DIPEPTIDE NITRILES | CTSL, CTSS, CTSB | SLC7A5 184/4885ADRB2 3888/4885ADRB1 2493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.